Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group (Q33503725)

27 July 2017

Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group (English)

1 reference

27 July 2017

0 references

1 reference

E J Estlin

1

1 reference

27 July 2017

L Lashford

2

1 reference

27 July 2017

S Ablett

3

1 reference

27 July 2017

L Price

4

1 reference

27 July 2017

R Gowing

5

1 reference

27 July 2017

A Gholkar

6

1 reference

27 July 2017

J Kohler

7

1 reference

27 July 2017

I J Lewis

8

1 reference

27 July 2017

B Morland

9

1 reference

27 July 2017

C R Pinkerton

10

1 reference

27 July 2017

M C Stevens

11

1 reference

27 July 2017

M Mott

12

1 reference

27 July 2017

R Stevens

13

1 reference

27 July 2017

D R Newell

14

1 reference

27 July 2017

D Walker

15

1 reference

27 July 2017

C Dicks-Mireaux

16

1 reference

27 July 2017

H McDowell

17

1 reference

27 July 2017

P Reidenberg

18

1 reference

27 July 2017

P Statkevich

19

1 reference

27 July 2017

A Marco

20

1 reference

27 July 2017

V Batra

21

1 reference

27 July 2017

M Dugan

22

1 reference

27 July 2017

A D Pearson

23

1 reference

27 July 2017

language of work or name

English

0 references

publication date

1 September 1998

1 reference

British Journal of Cancer

27 July 2017

1 reference

27 July 2017

78

1 reference

27 July 2017

652-661

1 reference

27 July 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.1998.555

27 July 2017

0 references

cites work

Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063055

Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063055

3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063055

Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063055

Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063055

Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063055

Simplified calculation of body-surface area.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063055

In vitro and in vivo methazolastone-induced DNA damage and repair in L-1210 leukemia sensitive and resistant to chloroethylnitrosoureas.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063055

O6-methylguanine-DNA methyltransferase in human normal and tumor tissue from brain, lung, and ovary.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063055

Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063055

Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063055

A comparison of two phase I trial designs.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063055

Tolerance to antineoplastic agents in children and adults

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/9744506

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/BJC.1998.555

1 reference

Dimensions Publication ID

27 July 2017

0 references

1 reference

27 July 2017

1 reference